1. Home
  2. TRVG vs CELC Comparison

TRVG vs CELC Comparison

Compare TRVG & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRVG
  • CELC
  • Stock Information
  • Founded
  • TRVG 2005
  • CELC 2011
  • Country
  • TRVG Germany
  • CELC United States
  • Employees
  • TRVG N/A
  • CELC N/A
  • Industry
  • TRVG EDP Services
  • CELC Medical Specialities
  • Sector
  • TRVG Technology
  • CELC Health Care
  • Exchange
  • TRVG Nasdaq
  • CELC Nasdaq
  • Market Cap
  • TRVG 306.5M
  • CELC 327.3M
  • IPO Year
  • TRVG N/A
  • CELC 2017
  • Fundamental
  • Price
  • TRVG $3.49
  • CELC $10.24
  • Analyst Decision
  • TRVG Hold
  • CELC Strong Buy
  • Analyst Count
  • TRVG 5
  • CELC 6
  • Target Price
  • TRVG $2.94
  • CELC $30.17
  • AVG Volume (30 Days)
  • TRVG 138.8K
  • CELC 392.7K
  • Earning Date
  • TRVG 04-29-2025
  • CELC 05-14-2025
  • Dividend Yield
  • TRVG N/A
  • CELC N/A
  • EPS Growth
  • TRVG N/A
  • CELC N/A
  • EPS
  • TRVG N/A
  • CELC N/A
  • Revenue
  • TRVG $477,118,749.00
  • CELC N/A
  • Revenue This Year
  • TRVG $9.20
  • CELC N/A
  • Revenue Next Year
  • TRVG $7.10
  • CELC N/A
  • P/E Ratio
  • TRVG N/A
  • CELC N/A
  • Revenue Growth
  • TRVG N/A
  • CELC N/A
  • 52 Week Low
  • TRVG $1.60
  • CELC $7.58
  • 52 Week High
  • TRVG $5.45
  • CELC $19.77
  • Technical
  • Relative Strength Index (RSI)
  • TRVG 41.83
  • CELC 54.38
  • Support Level
  • TRVG $3.25
  • CELC $7.58
  • Resistance Level
  • TRVG $3.80
  • CELC $10.48
  • Average True Range (ATR)
  • TRVG 0.44
  • CELC 1.04
  • MACD
  • TRVG -0.09
  • CELC 0.17
  • Stochastic Oscillator
  • TRVG 21.89
  • CELC 80.01

About TRVG trivago N.V.

trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments namely the Americas, Developed Europe, and the Rest of the World. It derives a majority of revenue from the Developed Europe segment. The Developed Europe segment is comprised of Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, Malta, the Netherlands, Norway, Portugal, Spain, Sweden, and others.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: